Detail akcie Ocular Therapeutix online

Business Summary: Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Ocular Therapeutix Inc revenues decreased 18% to $52M. Net loss increased 37% to $265.9M. Revenues reflect Collaboration revenue decrease of 51% to $128K. Higher net loss reflects ophthalmology segment loss increase of 57% to $270M, United States segment loss increase of 57% to $270M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.22 to -$1.42.